¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inspiratory phase time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • expiratory phase
    È£±â»ó
  • exponential phase
    Áö¼öÁõ½Ä±â
  • ejection phase
    ¹ÚÃâ±â
  • equilibrium phase
    ÆòÇü±â
  • erythrocytic phase
    ÀûÇ÷±¸³»¹ßÀ°±â
  • growth phase
    Áõ½Ä±â
  • intuitive phase
    Á÷°ü±â
  • involutional phase
    ÅðÈ­±â
  • isovolumic contraction phase
    µî¿ëÀû¼öÃà±â
  • implantational phase
    Âø»ó±â
  • inflow phase
    À¯ÀÔ±â
  • in-phase image
    À§»ó³»¿µ»ó
  • internal phase
    ºÐ»ê±â
  • latent phase
    1. ÀáÀç±â 2. Àẹ±â
  • leptotene phase
    °¡´Â¼¶À¯±â, ¼¼»ç±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • time-cycled ventilator
    ½Ã°£ÁÖ±âÈ£Èí±â
  • transit time
    ÀüÀ̽ð£, Åë°ú½Ã°£
  • travel time
    ÁÖÇà½Ã°£
  • utilization time
    ÀÌ¿ë½Ã°£
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • voiding time
    ¹è´¢½Ã°£
  • 3D phase contrast angiography
    »ïÂ÷¿øÀ§»ó´ëÁ¶Ç÷°üÁ¶¿µ¼ú
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • anal-sadistic phase
    Ç×¹®°¡Çбâ
  • phase advance
    À§»óÀüÁø
  • phase artifact
    À§»óÀΰø¹°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • go phase
    Á¤Áö±â Go±â
  • gradient induced phase shift effect
    °æ»ç À¯µµ À§»ó º¯À§ È¿°ú
  • grinding phase
    ºÐ¼â»ó.
  • implantational phase
    Âø»ó±â
  • in-phase image
    À§»ó³» ¿µ»ó
  • inactive phase
    ºñȰµ¿±â
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • phallic stage (phase)
    ³²±Ù±â(ÑûÐÆÑ¢).
  • phase
    »ó, ±â
  • phase
    ˤȗ
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • phase I block
    Á¦1»óÂ÷´Ü.
  • phase advance
    »óÀüÁø(ßÓîñòä)
  • phase angle
    À§»ó°¢(êÈßÓÊÇ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • left ventricular ejection time
    Á½ɽDZ¸Ç÷±â°£(¡­ÏÌúìÑ¢Êà).
  • longitudinal relaxation time
    Á¾Ãà ÀÌ¿Ï ½Ã°£
  • maximum phonation time
    ÃÖÀå ¹ß¼ºÁö¼Ó½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£(̰˻Ë×Ì¡Ëà˧).
  • mean tidal time =MTT
    Æò±Õ¼øÈ¯½Ã°£(¡­âàü»ãÁÊà).
  • mixing time
    ±³¹Ý½Ã°£(ÎæÚåãÁÊà).
  • nystagmus latent time
    ¾ÈÁø(ÀÇ) Àẹ½Ã°£
  • operative time
    ¼ö¼ú½Ã°£(¼ö¼ú½Ã°£).
  • partial prothrombin time
    ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • partial thromboplastin time =PTT
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£.
  • partial thromboplastin time=PTT
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£(õÌÍÔÒØöôãÁÊà).
  • perception time
    Áö°¢½Ã°£, ÀνĽð£.
  • persistence time
    Áö¼Ó½Ã°£(ò¥áÙãÁÊà).
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
FIVC forced inspiratory vital capacity
FVIC forced inspiratory vital capacity
I/E inspiratory/expiratory [ratio]; internal/external
I:E inspiratory/expiratory [ratio]
IFR infrared; inspiratory flow rate
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
MPF M phase promoting factor
MSPD Matrix Solid-Phase Dispersion
NP Normal-phase
PC Phase Contrast
PCM Phase contrast microscopy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • stationary phase of growth
    Áõ½Ä Á¤Áö±â
  • symbiotic phase
    °ø»ý±â
  • two-phase color reaction
    µÎ °¡Áö »ö±ò ¹ÝÀÀ
  • unequal phase
    ºñ´ëαâ
  • yeast phase
    È¿¸ð»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
phase contrast microscopy <investigation> A simple nonquantitative form of interference micoscopy of great utility in visualising live cells. Small differences in optical path length due to differences in refractive index and thickness of structures are visualised as differences in light intensity.
(18 Nov 1997)
phase, crystal <microscopy> A specific crystal structure, usually given a name.
(05 Aug 1998)
phase encoding In magnetic resonance imaging, the technique of inducing a gradient in the magnetic field in the Y-axis to induce phase differences with location.
Synonym: gradient encoding.
(05 Mar 2000)
phase I block Inhibition of nerve impulse transmission across the myoneural junction associated with depolarisation of the motor endplate, as in the muscle paralysis produced by succinylcholine.
(05 Mar 2000)
phase I clinical trial <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose.
They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies.
The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs.
(31 Dec 1997)
phase II block Inhibition of nerve impulse transmission across the myoneural junction unaccompanied by depolarisation of the motor endplate, as in the muscle paralysis produced by tubocurarine.
(05 Mar 2000)
phase II clinical trial <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study.
(31 Dec 1997)
phase III clinical trial <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments.
Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials.
(31 Dec 1997)
phase image A magnetic resonance image showing only phase shift information, to detect motion.
(05 Mar 2000)
phase plate <microscopy> The plate used near the back focal plane of a microscope objective lens (in conjunction with an annulus at the front focal plane of the condenser lens) to achieve phase contrast. The phase plate selectively shifts the phase of the waves diffracted by the specimen by a quarter wave and reduces the amplitude of the undeviated, direct beam.
(05 Aug 1998)
phase, resting More appropriately called interphase. The interval in the cell cycle between two cell divisions when the individual chromosomes cannot be distinguished, interphase was once thought to be the resting phase but it is far from a time of rest for the cell. It is the time when DNA is replicated in the cell nucleus.
(12 Dec 1998)
phase rule An expression of the relationships existing between systems in equilibrium: P + V = C + 2, where P is the number of phases, V the variance or degrees of freedom, and C the number of components; it also follows that the variance is, V = C + 2 -P. For H2O at its triple point, V = 1 + 2 -3 = 0, i.e., both temperature and pressure are fixed.
Synonym: Gibb's phase rule.
(05 Mar 2000)
phase separation <chemistry> The separation of fluid phases that contain different concentrations of common components.
Occurs with partially miscible solvents used in many biochemical separation methods. Also temperature dependent phase separation occurs with some detergent solutions. With reference to membranes means the segregation of lipid components into domains that have different chemical composition.
(31 Dec 1997)
phase shift <microscopy> A change in the phase relationship between two alternating quantities of the same frequency.
(05 Aug 1998)
phase variation <microbiology> Alteration in the expression of surface antigens by bacteria.
For example: Salmonella can express either of two forms of flagellin, H1 and H2, that are coded by different genes. Control of which form is expressed is brought about by inversion of the promoter for the H2 gene, which if functional (noninverted) is associated with the expression of H2 and the production of a repressor of the H1 gene.
Inversion occurs about every 1000 bacterial divisions and is under the control of another gene, hin, that is within the invertable sequence.
(31 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • time base
    ½Ã°£Ãà
  • time belt
    =time zone
  • time bill
    Á¤±âºÒ ¾à¼Ó ¾îÀ½
  • time bomb
    ½ÃÇÑÆøÅº
  • time capsule
    ŸÀÓĸ½¶(±× ½Ã´ë¸¦ ´ëÇ¥ÇÏ´Â ±â¹°,±â·ÏÀ» ¹Ì·¡¿¡ ³²±â±â À§Çؼ­ ³Ö¾îµÐ ±×¸©)
  • time card
    Áý¹« ½Ã°£ Ä«µå;±âÂ÷ ½Ã°£Ç¥
  • time charter
    Á¤±â ¿ë¼± °è¾à
  • time deposit
    Á¤±â ¿¹±Ý
  • time draft
    À϶÷ºÒ Á¤±â ¾îÀ½
  • time exposure
    ŸÀÓ ³ëÃâ(ÀÇ »çÁø)
  • time killer
    ½É½ÉÇ®À̰¡ µÇ´Â°Í
  • time lag
    ½Ã°£ÀÇ ¾î±ß³²;Áöü(·®)
  • time limit
    ½ÃÇÑ
  • time machine
    ŸÀӸӽŠ(°ú°Å³ª ¹Ì·¡¸¦ ¿©ÇàÇϱâ À§ÇÑ »ó»ó»óÀÇ ±â°è)
  • time note
    ¾à¼Ó¾îÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á